Age Later — Nir Barzilai (2020)

What it covers

• The Longevity Genes Project at Einstein College of Medicine and what Ashkenazi centenarians have taught us.
• The geroscience hypothesis: treating aging as the upstream modifier of multiple age-related diseases.
• The TAME trial of metformin in non-diabetic older adults and what it represents for regulatory acceptance of "geroprotector" drugs.
• Practical guidance more reserved than most popular longevity books.

Strengths

• Author runs one of the most respected centenarian-research programmes globally.
• More restrained on specific interventions than competing books.
• Honest about uncertainty and what hasn’t been proven.
• Sets out the regulatory-translational challenge geroscience faces.

What to read critically

• The metformin story specifically is more cautious than popular press; the book reflects this but readers expecting "take this drug" conclusions will be disappointed (probably appropriately).

Companion content

• AFAR (American Federation for Aging Research) materials.
• Barzilai’s ongoing TAME-funding updates.

Related entries

Nir Barzilai, TAME, Geroscience hypothesis, Metformin, Centenarians.